ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Regeneron Pharmaceuticals, Inc." (REGN) Report Updated: Oct 27, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Regeneron Pharmaceuticals, Inc." (REGN)

Rating: Buy Volatility: Conservative
Total Grade: B Industry: Biotechnology
Competitors: MNOV, CMRX, CBPO, ACHN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"Regeneron Pharmaceuticals, Inc."© quotemedia

Company Profile

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. The company’s commercial products include EYLEA (aflibercept) Injection for the treatment of neovascular age-related macular degeneration; and ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical development stage consists of EYLEA for the treatment of serious eye diseases; ZALTRAP (Aflibercept), which is developed in oncology; and ARCALYST for the prevention of gout flares in patients initiating uric acid-lowering treatment. The company’s earlier stage clinical programs include various human monoclonal antibodies, such as REGN727 for low-density lipoprotein cholesterol reduction; REGN88 for rheumatoid arthritis; REGN668 for atopic dermatitis and eosinophilic asthma; REGN421 and REGN910 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN728, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and Bayer HealthCare LLC to develop and commercialize ZALTRAP and EYLEA. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Recent News: "Regeneron Pharmaceuticals, Inc."